Abstract:Abstract Background: Thrombopoietin (TPO) is the primary regulator of platelet production. Recombinant human thrombopoietin (rHuTPO) and its derivative have been reported as potent drugs in treatment of chemotherapy induced thrombocytopenia and idiopathic thrombocytopenic purpura. Due to severe immunogenic adverse affects clinical applications of rHuTPO have been limited. However, new TPO receptor agonists that lack this adverse effect are developed. RHuTPO exhibits nonlinear kinetics and complex dynamics both mediated by binding to TPO receptor. Studies of rHuTPO pharmacokinetics (PK) and pharmacodynamics (PD) will facilitate future use of new TPO receptor agonists. Purpose: To analyze PK and PD of rHuTPO following a single IV bolus administration in rats. Methods: Adult male Wistar rats of body weight 300–600 g received a single dose of rHuTPO (ProSpec Ltd) (2.4, 4.8 and 9.6 μg/kg) and a placebo via an intravenous injection in tail. Blood samples (100–200μL) were collected at various hours during 3 days for PK analysis and every day for consecutive 14 days for PD assessment. RHuTPO plasma concentrations were measured using ELISA (R&D Systems Inc). Platelet count was determined using hematology analyzer (BC-2800 VET, Mindray). Noncompartmental parameters such as area under concentration curve (AUC), clearance (CL), volume at steady-state (Vss), and terminal half-life (t1/2) were calculated by WinNonlin 5.2 (Pharsight). Percent increase over the baseline for platelet maximum (%MPC) and area under the platelet response curve (%AUCPLT) were applied as PD markers. Student t-test was used to compare the means between control and treatment groups (SAS 9.1, SAS Institute). Results: CL decreased with increasing dose (0.185, 0.131, and 0.047 L/h/kg), similarly to Vss (3.28, 1.10, and 0.51 L). The t1/2 values were also dose dependent (13.2, 6.1, and 8.2 h). The %MPC values were 43, 77, and 45% for corresponding doses and the peaks occurred on days 5, 6, and 6 following rHuTPO administration. The %AUCPLT values were relatively insensitive to increasing doses (20, 23, and 13%). Both mean peak platelet counts and mean AUCPLT were significantly different (p < 0.05) from the control values with an exception of AUCPLT for dose 2.4 μg/kg. Conclusions: RHuTPO exhibits nonlinear pharmacokinetics in rat. CL and Vss dependence on dose suggests receptor mediated drug disposition as a major reason of nonlinear PK. IV bolus doses 2.4, 4.8 and 9.6 μg/kg of rHuTPO moderately increase platelet count in rats that peaks on day 5–6 after drug administration. The observed lack of the PD marker increase with increased doses implicates that the applied doses are in a flat region of the dose-response curve. Compared to similar data reported for humans, rHuTPO is less efficacious in rats than in humans.

Pharmacokinetics and pharmacodynamics of low doses of recombinant tissue plasminogen activator to establish a model for biosimilarity comparisons

Comparison of local thrombolytic efficacy of plasmin and rt-PA in an in-vitro flow system; a pilot study

Factors influencing the efficacy of recombinant tissue plasminogen activator: Implications for ischemic stroke treatment

Abstract 2329: A Randomized Double Blind, Placebo controlled Phase 1a Clinical Trial of THR-18, a PAI-1 Derived peptide, in Normal Volunteers

Systemic Thrombolysis With Recombinant Tissue Plasminogen Activator and Tirofiban in Acute Middle Cerebral Artery Occlusion

Clinical efficacy of low dose recombinant tissue-type plasminogen activator for the treatment of acute intermediate-risk pulmonary embolism

A Randomized Phase III Study to Compare Efficacy and Safety of BAT2206 (proposed Ustekinumab Biosimilar) with Reference Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis

A Randomized Phase 1 Pharmacokinetic Trial Comparing the Potential Biosimilar Pf-05280014 with Trastuzumab in Healthy Volunteers (reflections B327-01)

A PHARMACOECONOMIC ASSESSMENT OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR THERAPY FOR ACUTE ISCHEMIC STROKE IN A TERTIARY HOSPITAL IN CHINA

[An Economic Evaluation of Low Dose Recombinant Human Tissue-Type Plasminogen Activator for the Treatment of Acute Pulmonary Thromboembolism].

Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion

Proportion of single-chain recombinant tissue plasminogen activator and outcome after stroke

Pharmacokinetics and Pharamcodynamics of Recombinant Human Thrombopoietin Following Single Injection in Rats

Efficacy and Safety of Different Dosage of Recombinant Tissue-type Plasminogen Activator (rt-PA) in the Treatment of Acute Pulmonary Embolism: A Systematic Review and Meta-analysis

Influence of Thrombolysis on the Safety and Efficacy of Blocking Platelet Adhesion or Secretory Activity in Acute Ischemic Stroke in Mice

Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group

Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations

Single- and two- chain tissue type plasminogen activator treatments differentially influence cerebral recovery after stroke

Low thrombin generation predicts poor prognosis in ischemic stroke patients after thrombolysis

Thrombolysis with Recombinant Human Prourokinase 4.5-6 h After Acute Ischemic Stroke: A Phase IIa, Randomized, and Open-Label Multicenter Clinical Trial